| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Richard James Whitley is Director at GILD, with reported holdings spanning 2 companies. Richard James Whitley's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.5M at current prices.
Our model assigns Richard James Whitley a below-average insider score of 25/100, based on 5 past trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -72.5%.
Richard James Whitley's largest disclosed position is in GILD as Director, worth about $5.5M. The GILD filings lean toward selling, a net 39,350 shares.
Richard James Whitley has 38 Form 4 filings on record from March 2017 to June 2026, across 2 companies: Director at Dogwood Therapeutics (DWTX), 2021–2026; Director at Gilead Sciences (GILD), 2017–2021.
The 47 reported transactions were 33 option or other derivative awards, 7 option exercises, 4 open-market sales and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $14K and 4 sales worth about $2.6M.
The largest open-market purchase was 1,800 shares of DWTX at an average $5.72 on January 6, 2022, about $10K. Twelve months later DWTX was down 95%.
The largest open-market sale was 20,282 shares of GILD at an average $64.57 on May 3, 2021, about $1.3M. Twelve months later GILD was down 4%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Sell | 1,800 | $0.26 | $466.38 | -72.0% | +33.4% | +152.0% | |
| May 18, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 500 | $4.53 | $2,262.50 | +25.0% | +46.8% | -75.9% | |
| Jan 6, 2022 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 1,800 | $5.72 | $10,296.00 | +900.0% | -20.9% | -95.5% | |
| Dec 23, 2021 | DWTX Dogwood Therapeutics, Inc. | Director | Buy | 200 | $5.73 | $1,145.00 | New | -6.5% | -95.3% | |
| May 3, 2021 | GILD Gilead Sciences, Inc. | Director | Sale+OE | 20,282 | $64.57 | $1,309,655.39 | -39.5% | +5.0% | -4.3% | |
| May 1, 2019 | GILD Gilead Sciences, Inc. | Director | Sale+OE | 9,534 | $65.02 | $619,934.05 | -27.5% | - | - | |
| Apr 1, 2019 | GILD Gilead Sciences, Inc. | Director | Sale+OE | 9,534 | $65.48 | $624,254.86 | -27.5% | - | - |